Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Am J Transplant. 2015 Feb 20;15(4):984–992. doi: 10.1111/ajt.13100

Figure 4. ICOS-Ig does not promote rejection-free renal allograft survival.

Figure 4

Animals (n=3 per treatment group) received ICOS-Ig alone, belatacept alone, or combined ICOS-Ig and belatacept maintenance therapy after transplantation. Rejection-free survival is shown. Historical data from untreated controls are shown. ICOS-Ig did not prolong rejection-free renal allograft survival, either as monotherapy or in combination with belatacept.